Adaptive Virotherapy Strategy for Organism With Constrained Input Using Medicine Dosage Regulation Mechanism

The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study

“… 10 These examples illustrate that effective dosages of OVs can vary significantly depending on the specific condition and treatment context. 39 However, whether the effectiveness and toxicity of H101 are dose-dependent remains an open question. Our findings suggest the possibility of a wider safe dose than two vials for H101, which warrants further exploration.…”